Nilima Biswas

发表

Chromogranin A pathway: from pathogenic molecule to renal disease.

D. O'Connor, N. Webster, W. Cheung, 2019, Journal of hypertension.

Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: virtual screening and functional testing identify novel small molecule therapeutics of hypertension.

D. O'Connor, I. Tsigelny, V. Kouznetsova, 2013, Bioorganic & medicinal chemistry.

Human Cytomegalovirus Infection Leads to Accumulation of Geminin and Inhibition of the Licensing of Cellular DNA Replication

D. Spector, V. Sanchez, Nilima Biswas, 2003, Journal of Virology.

Spector the Licensing of Cellular DNA Replication Accumulation of Geminin and Inhibition of Human Cytomegalovirus Infection Leads to

V. Sanchez, Nilima Biswas, H. Deborah, 2003 .

MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension.

N. Schork, D. O'Connor, G. Schmid-Schönbein, 2013, Human molecular genetics.

A Common Genetic Variant in the 3′-UTR of Vacuolar H+-ATPase ATP6V0A1 Creates a Micro-RNA Motif to Alter Chromogranin A Processing and Hypertension Risk

D. O'Connor, L. Taupenot, Lei Wang, 2011, Circulation. Cardiovascular genetics.

Nicotinic acetylcholine receptors in glucose homeostasis: the acute hyperglycemic and chronic insulin-sensitive effects of nicotine suggest dual opposing roles of the receptors in male mice.

D. O'Connor, S. Mahata, J. Siddiqui, 2014, Endocrinology.

Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system

C. Nievergelt, D. O'Connor, D. Baker, 2016, BMC Medical Genetics.

A Novel Pathway of Insulin Sensitivity in Chromogranin A Null Mice

D. O'Connor, S. Najjar, S. Mahata, 2009, The Journal of Biological Chemistry.

Naturally Occurring Genetic Variants in Human Chromogranin A (CHGA) Associated with Hypertension as well as Hypertensive Renal Disease

C. Nievergelt, D. O'Connor, R. Salem, 2010, Cellular and Molecular Neurobiology.

Catestatin (Chromogranin A352–372) and Novel Effects on Mobilization of Fat from Adipose Tissue through Regulation of Adrenergic and Leptin Signaling*

Howon Lee, D. O'Connor, S. Mahata, 2012, The Journal of Biological Chemistry.

Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga364–384)

D. O'Connor, S. Mahata, Nilima Biswas, 2010, Cell and Tissue Research.

Discovery of a Novel Target for the Dysglycemic Chromogranin A Fragment Pancreastatin: Interaction with the Chaperone GRP78 to Influence Metabolism

D. O'Connor, S. Mahata, J. Gayen, 2014, PloS one.

Biogenesis of the secretory granule: chromogranin A coiled-coil structure results in unusual physical properties and suggests a mechanism for granule core condensation.

N. Schork, D. O'Connor, N. Olson, 2007, Biochemistry.

Deriving psychiatric symptom-based biomarkers from multivariate relationships between psychophysiological and biochemical measures

A. Minassian, C. Nievergelt, A. Simmons, 2022, Neuropsychopharmacology.

Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout.

D. O'Connor, Y. Li, A. Corti, 2010, Physiological genomics.

Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.

D. O'Connor, S. Mahata, M. Mahata, 2008, Endocrinology.

Chromogranin B: intra‐ and extra‐cellular mechanisms to regulate catecholamine storage and release, in catecholaminergic cells and organisms

D. O'Connor, S. Mahata, M. Mahata, 2014, Journal of neurochemistry.

Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders

H. Xin, N. Ferrara, Cuiling Zhong, 2021, Proceedings of the National Academy of Sciences.

Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses

D. O'Connor, Y. Li, S. Mahata, 2010, Journal of hypertension.

Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides.

D. O'Connor, J. Rodriguez-Flores, S. Mahata, 2009, Endocrinology.

Novel Peptide Isomer Strategy for Stable Inhibition of Catecholamine Release: Application to Hypertension

D. O'Connor, S. Mahata, M. Mahata, 2012, Hypertension.

LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy

Ruikang K. Wang, G. Paternostro, C. Piermarocchi, 2021, EMBO molecular medicine.

The UL5 and UL52 Subunits of the Herpes Simplex Virus Type 1 Helicase-Primase Subcomplex Exhibit a Complex Interdependence for DNA Binding*

S. Weller, Nilima Biswas, N. Biswas, 2001, The Journal of Biological Chemistry.

A Mutation in the C-terminal Putative Zn2+ Finger Motif of UL52 Severely Affects the Biochemical Activities of the HSV-1 Helicase-Primase Subcomplex*

S. Weller, Nilima Biswas, 1999, The Journal of Biological Chemistry.

A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function

C. Nievergelt, A. Schork, D. O'Connor, 2019, Scientific Reports.

Genetic variation at the delta‐sarcoglycan (SGCD) locus elevates heritable sympathetic nerve activity in human twin pairs

C. Nievergelt, A. Schork, D. O'Connor, 2013, Journal of neurochemistry.

Renal kallikrein excretion and epigenetics in human acute kidney injury: Expression, mechanisms and consequences

D. O'Connor, R. Mehta, M. Mahata, 2011, BMC nephrology.

Title Renal kallikrein excretion and epigenetics in human acute kidney injury : Expression , mechanisms and consequences Permalink

R. Mehta, M. Mahata, F. Rao, 2011 .

Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk.

C. Nievergelt, D. O'Connor, D. Baker, 2014, JAMA psychiatry.

Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity.

D. O'Connor, Yusu Gu, K. Peterson, 2010, Endocrinology.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses.

C. Nievergelt, N. Schork, A. Schork, 2012, Journal of the American College of Cardiology.

Genetic Variation in the Human Promoter Alters Glucocorticoid Signaling, Yielding Increased NPY Secretion and Stress Responses

C. Nievergelt, N. Schork, A. Schork, 2012 .

Identification of novel loci affecting circulating chromogranins and related peptides

C. Nievergelt, N. Schork, A. Schork, 2016, Human molecular genetics.

Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure

C. Nievergelt, A. Schork, D. O'Connor, 2012, Journal of hypertension.

Catecholamine Storage Vesicles: Role of Core Protein Genetic Polymorphisms in Hypertension

D. O'Connor, S. Mahata, M. Mahata, 2010, Current hypertension reports.

Online Supplement : Novel peptide isomer strategy for stable inhibition of catecholamine release : Application to hypertension

S. Mahata, M. Mahata, Ying Su, 2022 .

Chromogranin A pathway: from pathogenic molecule to renal disease.

D. O'Connor, N. Webster, W. Cheung, 2019, Journal of hypertension.